Top Markets
#1 MowCat MowCat +48.24%
#2 Velvet Velvet +24.18%
#3 Bitway Bitway +22.81%
#4 aPriori aPriori +19.56%
#5 OVERTAKE OVERTAKE +18.77%
#6 Biconomy Biconomy +15.79%
#7 Derive Derive +14.39%
#8 Zerebro Zerebro +12.76%
#9 DODO DODO +11.91%
#10 Perle Perle +11.36%
Coin of the day
MowCat MowCat
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
WPD Pharmaceuticals Inc. WPD Pharmaceuticals Inc.

WPD Pharmaceuticals Inc.

WBIO
Rang in Aktien #34463
WPD Pharmaceuticals Inc., a biopharmaceutical company based in Vancouver,... WPD Pharmaceuticals Inc., a biopharmaceutical company based in Vancouver, Canada, specializes in the research and advancement of therapeutic products for oncology and infectious diseases. The company's diverse drug development pipeline features multiple promising candidates: WPD101 and WPD103 are both in pre-clinical stages, targeting brain cancers, including glioblastoma and glioblastoma multiforme respectively. Also in pre-clinical development is WPD102, aimed at Uveal Melanoma. In more advanced clinical stages, Berubicin is undergoing Phase 1 trials for glioblastoma, while WP1066, also in Phase 1 clinical trials, is being investigated for central nervous system tumors, pancreatic cancer, and ocular tumors. Additionally, the pipeline includes WP1732 for pancreatic cancer and WP1220 for cutaneous T-cell lymphoma. Annamycin is currently in Phase I/II clinical trials for acute myeloid leukemia (AML) and is also being explored for lung metastasis.
Aktienkurs
$0.04895618
Zuletzt synchronisiert: 2025-03-18
Marktkapitalisierung
$5.55M
Veränderung (1 Tag)
-0.04%
Veränderung (1 Jahr)
0.00%
Land
CA
Handel WPD Pharmaceuticals Inc. (WBIO)

Kategorie

Healthcare
P/B-Verhältnis für WPD Pharmaceuticals Inc. (WBIO)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von WPD Pharmaceuticals Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für WPD Pharmaceuticals Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE